Warfarin monitoring therapy with

Standard monitoring of INR in patients taking warfarin should be performed when therapy with celecoxib or rofecoxib is begun or changed. 

Dicoumarol, warfarin + sulfadimethoxine, sulfamethoxypyridazine, sulfaphenazole Increased anticoagulant blood levels with risk of haemorrhage Displacement from protein by strongly bound sulfonamide Use alternative chemotherapy. Monitor patient with initiation of cessation of therapy... 

Warfarin + etacrynic acid Increased blood level of warfarin with haemorrhage risk Displacement from protein Monitor patient with initiation and cessation of therapy... 

Inform the patient about the potential drug-drug interactions with warfarin, including over-the-counter medications and dietary supplements (Tables 7-8, 7-9, and 7-10). Instruct the patient to call the health care practitioner responsible for monitoring warfarin therapy before starting any new medications or dietary supplements. 

Orlistat reduces the absorption of fat-soluble vitamins. Daily intake of a multivitamin containing vitamins A, D, E, and K, as well as 3-carotene, is recommended. Patients should take the multivitamin 2 hours prior to or after the dose of orlistat.31 Since availability of vitamin K may decline in patients receiving orlistat therapy, close monitoring of coagulation status should occur with concomitant administration of warfarin.31 Administration of orlistat in conjunction with cyclosporine can result in decreased cyclosporine plasma levels. To avoid this interaction, cyclosporine should be taken 2 hours preceding or following the dose of orlistat. Additionally, cyclosporine levels should be monitored more frequently.31... 

Coenzyme Q10 shares a structural similarity with vitamin K, and an interaction has been observed between coenzyme Q10 and warfarin. Coenzyme Q10 supplements may decrease the effects of warfarin therapy. This combination should be avoided or very carefully monitored. 

Uses. Warfarin is the oral anticoagulant of choice, for it is reliably effective and has the lowest incidence of adverse effects. Monitoring of therapy is by the prothrombin time. Usually the test is carried out with a standardised thromboplastin and the result is expressed as the International Normalised Ratio (INR), which is the ratio of the prothrombin time in the patient to that in a normal (non-anticoagulated) person—taking account of the sensitivity of the... 

---